Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Study of loncastuximab tesirine administered intravenously (IV) for maintenance therapy
following autologous stem cell transplant in patients with relapsed diffuse large B cell
lymphoma